Fate Therapeutics announced promising results from a Phase 1 trial for treating SLE with FT819. Out of 10 patients treated, all showed significant reductions in disease activity scores and favorable safety profiles, allowing for same-day discharge post-treatment. Patients with lupus nephritis achieved complete renal response. The treatment showed rapid depletion of CD19+ B cells and immune remodeling. The company plans to expand the program and initiate a pivotal study in 2026. FT819 demonstrates potential in transforming outcomes for patients with autoimmune diseases like SLE.

Read more at GlobeNewswire: Fate Therapeutics Presents New Clinical Data at ACR